Unicycive Therapeutics (UNCY) Expected to Release Earnings on Thursday

Unicycive Therapeutics (NASDAQ:UNCY) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.4710) per share and revenue of $22.2220 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:30 AM ET.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, analysts expect Unicycive Therapeutics to post $-1 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Unicycive Therapeutics Stock Down 0.4%

NASDAQ UNCY opened at $5.00 on Wednesday. The company has a 50-day simple moving average of $6.04 and a two-hundred day simple moving average of $6.67. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $8.74. The firm has a market cap of $136.95 million, a price-to-earnings ratio of -2.26 and a beta of 1.79.

Hedge Funds Weigh In On Unicycive Therapeutics

Several hedge funds have recently made changes to their positions in UNCY. State Street Corp boosted its holdings in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after acquiring an additional 10,400 shares in the last quarter. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics in the 2nd quarter worth $55,000. JPMorgan Chase & Co. lifted its position in shares of Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of Unicycive Therapeutics in the 4th quarter worth about $226,000. Finally, Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at about $182,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UNCY has been the subject of a number of recent research reports. Zacks Research lowered Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Benchmark decreased their price target on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research note on Wednesday, July 1st. Guggenheim reiterated a “buy” rating and issued a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a research report on Wednesday, May 13th. B. Riley Financial reissued a “buy” rating and set a $22.00 price objective on shares of Unicycive Therapeutics in a research note on Tuesday, June 30th. Finally, HC Wainwright cut their target price on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Five analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $21.75.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.